TY - JOUR AU - Yous, S. AU - Andrieux, J. AU - Howell, H. E. AU - Morgan, P. J. AU - Renard, P. AU - Pfeiffer, B. PY - 1992 DA - 1992// TI - Novel naphthalenic ligands with high affinity for the melatonin receptor JO - J Med Chem VL - 35 UR - https://doi.org/10.1021/jm00086a018 DO - 10.1021/jm00086a018 ID - Yous1992 ER - TY - STD TI - Servier Laboratories Limited: Summary of product characteristics: Valdoxan 25 mg film-coated tablets [http://www.medicines.org.uk/emc/medicine/21830/SPC/valdoxan/] UR - http://www.medicines.org.uk/emc/medicine/21830/SPC/valdoxan/ ID - ref2 ER - TY - STD TI - Therapeutic Goods Administration, Department of Health and Ageing: Australian public assessment report for agomelatine [http://www.tga.gov.au/pdf/auspar/auspar-valdoxan.pdf] UR - http://www.tga.gov.au/pdf/auspar/auspar-valdoxan.pdf ID - ref3 ER - TY - JOUR AU - Taylor, D. AU - Sparshatt, A. AU - Varma, S. AU - Olofinjana, O. PY - 2014 DA - 2014// TI - Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies JO - BMJ VL - 348 ID - Taylor2014 ER - TY - JOUR AU - Guaiana, G. AU - Gupta, S. AU - Chiodo, D. AU - Davies, S. J. C. AU - Haederle, K. AU - Koesters, M. PY - 2013 DA - 2013// TI - Agomelatine versus other antidepressive agents for major depression JO - Cochrane Database Syst Rev VL - 12 ID - Guaiana2013 ER - TY - JOUR AU - Navarro, V. AU - Senior, J. R. PY - 2006 DA - 2006// TI - Drug-related hepatotoxicity JO - N Engl J Med VL - 354 UR - https://doi.org/10.1056/NEJMra052270 DO - 10.1056/NEJMra052270 ID - Navarro2006 ER - TY - JOUR AU - Voican, C. S. AU - Corruble, E. AU - Naveau, S. AU - Perlemuter, G. PY - 2014 DA - 2014// TI - Antidepressant-induced liver injury: a review for clinicians JO - Am J Psychiatry VL - 171 UR - https://doi.org/10.1176/appi.ajp.2013.13050709 DO - 10.1176/appi.ajp.2013.13050709 ID - Voican2014 ER - TY - STD TI - European Medicines Agency: Evaluation of medicines for human use—CHMP assessment report for Valdoxan [http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-Public_assessment_report/human/000915/WC500046226.pdf] UR - http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-Public_assessment_report/human/000915/WC500046226.pdf ID - ref8 ER - TY - STD TI - Drug safety update, Medicines and Healthcare products Regulatory Agency: Agomelatine (Valdoxan/Thymanax): risk of dose-related hepatotoxicity and liver failure—update warnings and monitoring guidance [http://www.mhra.gov.uk/home/groups/dsu/documents/publication/con199577.pdf] UR - http://www.mhra.gov.uk/home/groups/dsu/documents/publication/con199577.pdf ID - ref9 ER - TY - STD TI - Servier Laboratories Limited: Agomelatine (Valdoxan): monitor liver function and do not use in people with high serum transaminase levels (>3 x ULN) or ≥ 75 years [http://www.servier.co.uk/pdfs/direct-healthcare-professional-communication.pdf] UR - http://www.servier.co.uk/pdfs/direct-healthcare-professional-communication.pdf ID - ref10 ER - TY - JOUR AU - Temple, R. J. AU - Himmel, M. H. PY - 2002 DA - 2002// TI - Safety of newly approved drugs: implications for prescribing JO - JAMA VL - 287 UR - https://doi.org/10.1001/jama.287.17.2273 DO - 10.1001/jama.287.17.2273 ID - Temple2002 ER - TY - STD TI - European Medicines Agency, Committee for Medicinal Products for Human Use: Reflection paper on non-clinical evaluation of drug-induced liver injury [http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/07/WC500094591.pdf UR - http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/07/WC500094591.pdf ID - ref12 ER - TY - STD TI - Novartis clinical trial results database: CAGO178: Major Depressive Disorder (MDD) [http://wwctrdW/ctrdWebApp/clinicaltrialrepository/public/product.jsp?productID=268&diseaseAreaID=3] UR - http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/public/product.jsp?productID=268&diseaseAreaID=3 ID - ref13 ER - TY - STD TI - Antidepressiva Forum Deutschland Wissen: Agomelatin/Studien [http://www.adfd.org/wissen/Agomelatin/Studien] UR - http://www.adfd.org/wissen/Agomelatin/Studien ID - ref14 ER - TY - JOUR AU - Li, J. Z. AU - Bunney, B. G. AU - Meng, F. AU - Hagenauer, M. H. AU - Walsh, D. M. AU - Vawter, M. P. PY - 2013 DA - 2013// TI - Circadian patterns of gene expression in the human brain and disruption in major depressive disorder JO - Proc Natl Acad Sci U S A VL - 110 UR - https://doi.org/10.1073/pnas.1305814110 DO - 10.1073/pnas.1305814110 ID - Li2013 ER - TY - JOUR AU - Audinot, V. AU - Mailliet, F. AU - Lahaye-Brasseur, C. AU - Bonnaud, A. AU - Gall, A. AU - Amossé, C. PY - 2003 DA - 2003// TI - New selective ligands of human cloned melatonin MT1 and MT2 receptors JO - Naunyn Schmiedeberg’s Arch Pharmacol VL - 367 UR - https://doi.org/10.1007/s00210-003-0751-2 DO - 10.1007/s00210-003-0751-2 ID - Audinot2003 ER - TY - JOUR AU - Millan, M. J. AU - Gobert, A. AU - Lejeune, F. AU - Dekeyne, A. AU - Newman-Tancredi, A. AU - Pasteau, V. PY - 2003 DA - 2003// TI - The novel melatonin agonist Agomelatine (S20098) is anantagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways JO - J Pharmacol Exp Ther VL - 306 UR - https://doi.org/10.1124/jpet.103.051797 DO - 10.1124/jpet.103.051797 ID - Millan2003 ER - TY - JOUR AU - Quera-Slava, M. A. AU - Vanier, B. AU - Laredo, J. AU - Hartley, S. AU - Chapotot, F. AU - Moulin, C. PY - 2007 DA - 2007// TI - Major depressive disorder, sleep EEG and agomelatine: an open-label study JO - Int J Neuropsychopharmacol VL - 10 ID - Quera-Slava2007 ER - TY - JOUR AU - Berardis, D. AU - Iorio, G. AU - Acciavatti, T. AU - Conti, C. AU - Serroni, N. AU - Olivieri, L. PY - 2011 DA - 2011// TI - The emerging role of melatonin agonists in the treatment of major depression: Focus on agomelatine JO - CNS Neurol Disord Drug Targets VL - 10 UR - https://doi.org/10.2174/187152711794488674 DO - 10.2174/187152711794488674 ID - Berardis2011 ER - TY - JOUR AU - Gahr, M. AU - Freudenmann, R. W. AU - Connenmann, B. J. AU - Hiemke, C. AU - Schönfeldt-Lecuona, C. PY - 2013 DA - 2013// TI - Agomelatine and hepatotoxicity: implications of cumulated data derived from spontaneous reports of adverse drug reactions JO - Pharmacopsychiatry VL - 46 UR - https://doi.org/10.1055/s-0033-1353156 DO - 10.1055/s-0033-1353156 ID - Gahr2013 ER - TY - JOUR AU - Hussaini, S. H. AU - Farrington, E. A. PY - 2007 DA - 2007// TI - Idiosyncratic drug-induced liver injury: an overview JO - Expert Opin Drug Saf VL - 6 UR - https://doi.org/10.1517/14740338.6.6.673 DO - 10.1517/14740338.6.6.673 ID - Hussaini2007 ER - TY - JOUR AU - Zajecka, J. AU - Schatzberg, A. AU - Stahl, S. AU - Shah, A. AU - Caputo, A. AU - Post, A. PY - 2010 DA - 2010// TI - Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial JO - J Clin Psychopharmacol VL - 30 UR - https://doi.org/10.1097/JCP.0b013e3181d420a7 DO - 10.1097/JCP.0b013e3181d420a7 ID - Zajecka2010 ER - TY - STD TI - Novartis clinical trial results database, Study number CAGO178A2301: An 8-week, randomized, double-blind, fixed dosage, placebo-controlled, parallel-group, multi-center study of the efficacy, safety and tolerability of agomelatine 25 mg and 50 mg in the treatment of Major Depressive Disorder (MDD). [http://wwctrdW/ctrdWebApp/clinicaltrialrepository/public/product.jsp?productID=268&diseaseAreaID=3] UR - http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/public/product.jsp?productID=268&diseaseAreaID=3 ID - ref23 ER - TY - JOUR AU - Stahl, S. AU - Fava, M. AU - Trivedi, M. H. AU - Caputo, A. AU - Shah, A. AU - Post, A. PY - 2010 DA - 2010// TI - Agomelatine in the treatment of Major Depressive Disorder: an 8-week, multicenter, randomized, placebo-controlled trial JO - J Clin Psychiatry VL - 71 UR - https://doi.org/10.4088/JCP.09m05471blu DO - 10.4088/JCP.09m05471blu ID - Stahl2010 ER - TY - STD TI - Novartis clinical trial results database, Study number CAGO178A2302: An 8-week, randomized, double-blind, fixed dosage, placebo-controlled, parallel-group, multi-centerstudy of the efficacy, safety and tolerability of agomelatine 25 mg and 50 mg in the treatment of Major Depressive Disorder (MDD) [http://wwctrdW/ctrdWebApp/clinicaltrialrepository/public/product.jsp?productID=268&diseaseAreaID=3] UR - http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/public/product.jsp?productID=268&diseaseAreaID=3 ID - ref25 ER - TY - STD TI - Novartis clinical trial results database, Study number CAGO178A2303: An 8-weel, multicenter, randomized, double-blind, placebo- and paroxetine-controlled study of the efficacy, safety and tolerability of agomelatine 25 or 50 mg given once daily in the treatment of Major Depressive Disorder (MDD) [http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/public/product.jsp?productID=268&diseaseAreaID=3] UR - http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/public/product.jsp?productID=268&diseaseAreaID=3 ID - ref26 ER - TY - JOUR AU - Hale, A. AU - Corral, R. M. AU - Mencacci, C. AU - Ruiz, J. S. AU - Severo, C. A. AU - Gentil, V. PY - 2010 DA - 2010// TI - Superior efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study JO - Int Clin Psychopharmacol VL - 25 UR - https://doi.org/10.1097/YIC.0b013e32833a86aa DO - 10.1097/YIC.0b013e32833a86aa ID - Hale2010 ER - TY - JOUR AU - Kasper, S. AU - Hajak, G. AU - Wulff, K. AU - Hoogendijk, W. J. C. AU - Montejo, A. L. AU - Smeraldi, E. PY - 2010 DA - 2010// TI - Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with Major Depressive Disorder: a randomized, double-blind comparison with sertraline JO - J Clin Psychiatry VL - 71 UR - https://doi.org/10.4088/JCP.09m05347blu DO - 10.4088/JCP.09m05347blu ID - Kasper2010 ER - TY - STD TI - Novartis clinical trial results database, Study number CAGO178A2301E1: A 52-week, open-label extension to an 8-week, randomized, double-blind, fixed dosage, placebo-controlled, parallel-group, multi-center study of the efficacy, safety and tolerability of agomelatine 25 mg and 50 mg in the treatment of Major Depressive Disorder [http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/public/product.jsp?productID=268&diseaseAreaID=3] UR - http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/public/product.jsp?productID=268&diseaseAreaID=3 ID - ref29 ER - TY - STD TI - Novartis clinical trial results database, Study number CAGO178A2302E1: A 52-week, open-label extension to an 8-week, randomized, double-blind, fixed dosage, placebo-controlled, parallel-group, multi-center study of the efficacy, safety and tolerability of agomelatine 25 mg and 50 mg in the treatment of Major Depressive Disorder [http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/public/product.jsp?productID=268&diseaseAreaID=3] UR - http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/public/product.jsp?productID=268&diseaseAreaID=3 ID - ref30 ER - TY - STD TI - Novartis clinical trial results database, Study number CAGO178A2303E1: A 52-week, open-label extension to Study AGO178A2303, an 8-week, multicenter, randomized, double-blind, placebo- and paroxetine-controlled study of the efficacy, safety and tolerability of agomelatine 25 or 50 mg given once daily in the treatment of Major Depressive Disorder [http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/public/product.jsp?productID=268&diseaseAreaID=3] UR - http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/public/product.jsp?productID%20=%20268&diseaseAreaID=3 ID - ref31 ER - TY - STD TI - Novartis clinical trial results database, Study number CAGO178A2304: A 52-week, randomized, double-blind, placebo-controlled, multicenter, parallel-group study of the long-term efficacy, tolerability and safety of agomelatine 25 and 50 mg in the prevention of relapse of Major Depressive Disorder (MDD) following open-label treatment of 16-24 weeks [http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/public/product.jsp?productID=268&diseaseAreaID=3] UR - http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/public/product.jsp?productID=268&diseaseAreaID=3 ID - ref32 ER - TY - JOUR AU - Calabrese, J. R. AU - Guelfi, J. D. AU - Perdrizet-Chevallier, C. PY - 2007 DA - 2007// TI - Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data JO - Bipolar Disord VL - 9 UR - https://doi.org/10.1111/j.1399-5618.2007.00507.x DO - 10.1111/j.1399-5618.2007.00507.x ID - Calabrese2007 ER - TY - JOUR AU - Olié, J. P. AU - Kasper, S. PY - 2007 DA - 2007// TI - Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder JO - Int J Neuropsychopharmacol VL - 10 ID - Olié2007 ER - TY - JOUR AU - Goodwin, G. M. AU - Emsley, R. AU - Rembry, S. AU - Rouillon, F. PY - 2009 DA - 2009// TI - Agomelatine prevents relapse in patients with Major Depressive Disorder without evidence of a discontination syndrome: a 24-week randomized, double-blind, placebo-controlled trial JO - J Clin Psychiatry VL - 70 UR - https://doi.org/10.4088/JCP.08m04548 DO - 10.4088/JCP.08m04548 ID - Goodwin2009 ER - TY - JOUR AU - Demyttenaere, K. AU - Corruble, E. AU - Hale, A. AU - Quera-Slava, M. A. AU - Picarel-Blanchot, F. AU - Kasper, S. PY - 2012 DA - 2012// TI - A pooled analysis of six month comparative efficacy and tolerability in four randomized clinical trials: agomelatine versus escitalopram, fluoxetine, and sertraline JO - CNS Spectr VL - 18 UR - https://doi.org/10.1017/S1092852913000060 DO - 10.1017/S1092852913000060 ID - Demyttenaere2012 ER - TY - JOUR AU - Bruno, A. AU - Micò, U. AU - Lorusso, S. AU - Cogliandro, N. AU - Pandolfo, G. AU - Caminiti, M. PY - 2013 DA - 2013// TI - Agomelatine in the treatment of fibromyalgia: a 12-week, open-label, uncontrolled preliminary study JO - J Clin Psychopharmacol VL - 33 UR - https://doi.org/10.1097/JCP.0b013e31829057ae DO - 10.1097/JCP.0b013e31829057ae ID - Bruno2013 ER - TY - JOUR AU - Martinotti, G. AU - Sepede, G. AU - Gambi, F. AU - Iorio, G. AU - Berardis, D. AU - Nicola, M. PY - 2012 DA - 2012// TI - Agomelatine versus venlafaxine XR in the treatment of anhedonia in major depressive disorder: a pilot study JO - J Clin Psychopharmacol VL - 32 UR - https://doi.org/10.1097/JCP.0b013e31825d6c25 DO - 10.1097/JCP.0b013e31825d6c25 ID - Martinotti2012 ER - TY - JOUR AU - Stein, D. AU - Ahokas, A. AU - Albarran, C. AU - Olivier, V. AU - Allgulander, C. PY - 2012 DA - 2012// TI - Agomelatine prevents relapse in Generalized Anxiety Disorder: a 6-month randomized, double-blind, placebo-controlled discontinuation study JO - J Clin Psychiatry VL - 3 UR - https://doi.org/10.4088/JCP.11m07493 DO - 10.4088/JCP.11m07493 ID - Stein2012 ER - TY - JOUR AU - Stein, D. J. AU - Ahokas, A. AU - Marquez, M. AU - Höschl, C. AU - Oh, K. S. AU - Jarema, M. PY - 2014 DA - 2014// TI - Agomelatine in Generalized Anxiety Disorder: an active comparator and placebo-controlled study JO - J Clin Psychiatry VL - 75 UR - https://doi.org/10.4088/JCP.13m08433 DO - 10.4088/JCP.13m08433 ID - Stein2014 ER - TY - JOUR AU - Heun, R. AU - Ahokas, A. AU - Boyer, P. AU - Giménez-Montesinos, N. AU - Pontes-Soares, F. AU - Olivier, V. PY - 2013 DA - 2013// TI - The efficacy of agomelatine in elderly patients with recurrent Major Depressive Disorder: a placebo-controlled study JO - J Clin Psychiatry VL - 74 UR - https://doi.org/10.4088/JCP.12m08250 DO - 10.4088/JCP.12m08250 ID - Heun2013 ER - TY - JOUR AU - Laux, G. PY - 2012 DA - 2012// TI - The antidepressant agomelatine in daily practice: results of the non-interventional study VIVALDI JO - Pharmacopsychiatry VL - 45 UR - https://doi.org/10.1055/s-0032-1309003 DO - 10.1055/s-0032-1309003 ID - Laux2012 ER - TY - JOUR AU - Sparshatt, A. AU - McAllister, W. R. H. AU - Baldwin, D. S. AU - Haddad, P. M. AU - Bazire, S. AU - Weston, E. PY - 2013 DA - 2013// TI - A naturalistic evaluation and audit database of agomelatine: clinical outcome at 12 weeks JO - Acta Psychiatr Scand VL - 128 UR - https://doi.org/10.1111/acps.12044 DO - 10.1111/acps.12044 ID - Sparshatt2013 ER - TY - JOUR AU - Karaiskos, D. AU - Tzavellas, E. AU - Illias, I. AU - Liappas, I. AU - Paparrigopoulos, T. PY - 2013 DA - 2013// TI - Agomelatine and sertraline for the treatment of depression in type 2 diabetes mellitus JO - Int J Clin Pract VL - 67 UR - https://doi.org/10.1111/ijcp.12112 DO - 10.1111/ijcp.12112 ID - Karaiskos2013 ER - TY - JOUR AU - Quera-Salva, M. A. AU - Hajak, G. AU - Philip, P. AU - Montplaisir, J. AU - Keufer-Le Gall, S. AU - Laredo, J. PY - 2011 DA - 2011// TI - Comparison of agomelatine and escitalopram on nighttime sleep and daytime condition and efficacy in major depressive disorder patients JO - Int Clin Psychopharmacol VL - 26 UR - https://doi.org/10.1097/YIC.0b013e328349b117 DO - 10.1097/YIC.0b013e328349b117 ID - Quera-Salva2011 ER - TY - JOUR AU - Montejo, A. L. AU - Prieto, N. AU - Terleira, A. AU - Matias, J. AU - Alonso, S. AU - Paniagua, G. PY - 2010 DA - 2010// TI - Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQSALSEX scale JO - J Psychopharmacol VL - 24 UR - https://doi.org/10.1177/0269881108096507 DO - 10.1177/0269881108096507 ID - Montejo2010 ER - TY - JOUR AU - Štuhec, M. PY - 2013 DA - 2013// TI - Agomelatine-induced hepatotoxicity JO - Wien Klin Wochenschr VL - 125 UR - https://doi.org/10.1007/s00508-013-0344-0 DO - 10.1007/s00508-013-0344-0 ID - Štuhec2013 ER - TY - JOUR AU - Montastruc, F. AU - Scotto, S. AU - Vaz, I. R. AU - Guerra, L. N. AU - Escudero, A. AU - Sainz, M. PY - 2014 DA - 2014// TI - Hepatotoxicity related to agomelatine and other new antidepressants: a case/noncase approach with information from the Portuguese, French, Spanish, and Italian pharmacovigilance systems JO - J Clin Psychopharmacol VL - 2014 UR - https://doi.org/10.1097/JCP.0000000000000094 DO - 10.1097/JCP.0000000000000094 ID - Montastruc2014 ER - TY - JOUR AU - Lammert, C. AU - Einarsson, S. AU - Saha, C. AU - Niklasson, A. AU - Bjornsson, E. AU - Chalasani, N. PY - 2008 DA - 2008// TI - Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals JO - Hepatology VL - 47 UR - https://doi.org/10.1002/hep.22272 DO - 10.1002/hep.22272 ID - Lammert2008 ER - TY - JOUR AU - Howland, R. H. PY - 2011 DA - 2011// TI - A benefit-risk assessment of agomelatine in the treatment of major depression JO - Drug Saf VL - 34 UR - https://doi.org/10.2165/11593960-000000000-00000 DO - 10.2165/11593960-000000000-00000 ID - Howland2011 ER - TY - JOUR AU - McIntyre, R. S. AU - Panjwani, Z. D. AU - Nguyen, H. T. AU - Woldeyohannes, H. O. AU - Alsuwaidan, M. AU - Soczynska, J. K. PY - 2008 DA - 2008// TI - The hepatic safety profile of duloxetine: a review JO - Expert Opin Drug Metab Toxicol VL - 4 UR - https://doi.org/10.1517/17425255.4.3.281 DO - 10.1517/17425255.4.3.281 ID - McIntyre2008 ER - TY - JOUR AU - Neuschwander-Tetri, B. A. AU - Caldwell, S. H. PY - 2003 DA - 2003// TI - Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference JO - Hepatology VL - 37 UR - https://doi.org/10.1053/jhep.2003.50193 DO - 10.1053/jhep.2003.50193 ID - Neuschwander-Tetri2003 ER - TY - JOUR AU - Rosenzweig, P. AU - Miget, N. AU - Brohier, S. PY - 1999 DA - 1999// TI - Transaminase elevation on placebo during Phase I trials: prevalence and significance JO - Br J Clin Pharmacol VL - 48 UR - https://doi.org/10.1046/j.1365-2125.1999.00952.x DO - 10.1046/j.1365-2125.1999.00952.x ID - Rosenzweig1999 ER - TY - JOUR AU - Jacob, D. AU - Marrón, B. AU - Ehrlich, J. AU - Rutherford, P. A. PY - 2013 DA - 2013// TI - Pharmacovigilance as a tool for safety and monitoring: a review of general issues and the specific challenges with end-stage renal failure JO - Drug Healthc Patient Saf VL - 5 ID - Jacob2013 ER - TY - JOUR AU - Verma, S. AU - Kaplowitz, N. PY - 2009 DA - 2009// TI - Diagnosis, management, and prevention of drung-induced liver injury JO - Gut VL - 58 UR - https://doi.org/10.1136/gut.2008.163675 DO - 10.1136/gut.2008.163675 ID - Verma2009 ER - TY - JOUR AU - Aithal, G. P. AU - Watkins, P. B. AU - Andrade, R. J. AU - Larrey, D. AU - Molokhia, M. AU - Takikawa, H. PY - 2011 DA - 2011// TI - Case definition and phenotype standardization in drug-induced liver injury JO - Clin Pharmacol Ther VL - 89 UR - https://doi.org/10.1038/clpt.2011.58 DO - 10.1038/clpt.2011.58 ID - Aithal2011 ER - TY - JOUR AU - Gachon, F. AU - Firsov, D. PY - 2011 DA - 2011// TI - The role of circadian timing system on drug metabolism and detoxification JO - Expert Opin Drug Metab Toxicol VL - 7 UR - https://doi.org/10.1517/17425255.2011.544251 DO - 10.1517/17425255.2011.544251 ID - Gachon2011 ER -